| Dramatic changes in oncology care pathways during the COVID‐19 pandemic: the French ONCOCARE‐COV study M Brugel, C Carlier, C Essner, A Debreuve‐Theresette, MF Beck, ... The Oncologist 26 (2), e338-e341, 2021 | 53 | 2021 |
| Impact of the COVID-19 pandemic on disease stage and treatment for patients with pancreatic adenocarcinoma: a French comprehensive multicentre ambispective observational cohort … M Brugel, L Letrillart, C Evrard, A Thierry, D Tougeron, M El Amrani, ... European Journal of Cancer 166, 8-20, 2022 | 20 | 2022 |
| Efficacy of treatments for VIPoma: A GTE multicentric series M Brugel, T Walter, B Goichot, D Smith, C Lepage, C Do Cao, ... Pancreatology 21 (8), 1531-1539, 2021 | 19 | 2021 |
| Pesticides and pancreatic adenocarcinoma: A transversal epidemiological, environmental and mechanistic narrative review M Brugel, C Carlier, G Reyes-Castellanos, S Callon, A Carrier, O Bouché Digestive and Liver Disease 54 (12), 1605-1613, 2022 | 13 | 2022 |
| Impact of guidelines regarding dihydropyrimidine dehydrogenase (DPD) deficiency screening using uracil-based phenotyping on the reduction of severe side effect of 5 … N Laures, C Konecki, M Brugel, AL Giffard, N Abdelli, D Botsen, C Carlier, ... Pharmaceutics 14 (10), 2119, 2022 | 12 | 2022 |
| Renal impairment and abnormal liver function tests in pre-therapeutic phenotype-based DPD deficiency screening using uracilemia: a comprehensive population-based study in 1138 … S Callon, M Brugel, D Botsen, B Royer, F Slimano, C Feliu, C Gozalo, ... Therapeutic Advances in Medical Oncology 15, 17588359221148536, 2023 | 10 | 2023 |
| Cannabidiol–drug interaction in cancer patients: A retrospective study in a real‐life setting M Guedon, A Le Bozec, M Brugel, J Clarenne, C Carlier, M Perrier, ... British Journal of Clinical Pharmacology 89 (7), 2322-2328, 2023 | 9 | 2023 |
| Prognostic factors and survival score for patients with anaplastic thyroid carcinoma: a retrospective study from a regional registry C Marchand-Crety, M Pascard, A Debreuve-Theresette, L Ettalhaoui, ... Anticancer Research 41 (3), 1555-1561, 2021 | 7 | 2021 |
| Time intervals to diagnosis and chemotherapy do not influence survival outcome in patients with advanced pancreatic adenocarcinoma. Q Laurent-Badr, C Barbe, M Brugel, V Hautefeuille, J Volet, S Grelet, ... Digestive and Liver Disease 52 (6), 658-667, 2020 | 7 | 2020 |
| Incidence and associated factors of cetuximab-induced hypersensitivity infusion reactions in 1392 cancer patients treated in four French areas: a possible association with Lyme … M Dupont, C Carlier, C Gower-Rousseau, P Barbier-Lider, D Botsen, ... BMC cancer 22 (1), 1219, 2022 | 6 | 2022 |
| Identification of protease-sensitive but not misfolding PNLIP variants in familial and hereditary pancreatitis E Masson, S Berthet, G Le Gac, M Le Rhun, C Ka, S Autret, I Gourlaouen, ... Pancreatology 23 (5), 507-511, 2023 | 5 | 2023 |
| One‐year COVID‐19 outcomes on the oncology care patient pathway: Results of a French descriptive, cross‐sectional comprehensive study (ONCOCARE‐COV) L Laurent, M Brugel, C Carlier, F Clere, A Bertrand, D Botsen, ... Cancer Medicine 11 (24), 4865-4879, 2022 | 5 | 2022 |
| Neoadjuvant chemotherapy for borderline resectable and upfront resectable pancreatic cancer increasing overall survival and disease-free survival? V Fossaert, A Mimmo, R Rhaiem, LJ Rached, M Brasseur, M Brugel, ... Frontiers in Oncology 12, 980659, 2022 | 4 | 2022 |
| Classification of PRSS1 variants responsible for chronic pancreatitis: An expert perspective from the Franco-Chinese GREPAN Study Group E Masson, WB Zou, N Pu, V Rebours, E Génin, H Wu, JH Lin, YC Wang, ... Pancreatology 23 (5), 491-506, 2023 | 3 | 2023 |
| Recent (non-cirrhotic) extrahepatic portal vein obstruction A Heurgué, D Habes, M Brugel, S Franchi-Abella, B Condat, D Valla, ... Clinics and Research in Hepatology and Gastroenterology 44 (4), 460-465, 2020 | 3 | 2020 |
| Characteristics and treatment options of glucagonomas: a national study from the French Group of Endocrine Tumors and ENDOCAN-RENATEN network M Perrier, M Brugel, L Gérard, B Goichot, A Lièvre, C Lepage, ... European Journal of Endocrinology 189 (6), 575-583, 2023 | 2 | 2023 |
| Beta-blocker exposure and survival outcomes in patients with advanced pancreatic ductal adenocarcinoma: a retrospective cohort study (BETAPANC) A Le Bozec, M Brugel, Z Djerada, M Ayad, M Perrier, C Carlier, D Botsen, ... Frontiers in Pharmacology 14, 1137791, 2023 | 2 | 2023 |
| Reperfused human cadaver as a new simulation model for colonoscopy: a pilot study A Rohr, C Perrenot, A Pitta, I Celerier, M Labrousse, Y Renard, G Cadiot, ... Surgical Endoscopy 37 (4), 3224-3232, 2023 | 2 | 2023 |
| The PRSS3P2 and TRY7 deletion copy number variant modifies risk for chronic pancreatitis E Masson, M Ewers, S Paliwal, K Kume, V Scotet, DN Cooper, V Rebours, ... Pancreatology 23 (1), 48-56, 2023 | 2 | 2023 |
| Time from first seen in specialist care to surgery does not influence survival outcome in patients with upfront resected pancreatic adenocarcinoma M Brugel, O Bouché, R Kianmanesh, L Teuma, A Tashkandi, ... BMC surgery 21, 1-12, 2021 | 2 | 2021 |
